MR22
目录号 : GC92711MR22 is an inhibitor of salt-inducible kinase (SIK; IC50s = 72, 89, and 18 nM for SIK1, SIK2, and SIK3, respectively).
Cas No.:3027761-24-3
Sample solution is provided at 25 µL, 10mM.
MR22 is an inhibitor of salt-inducible kinase (SIK; IC50s = 72, 89, and 18 nM for SIK1, SIK2, and SIK3, respectively). It is selective for SIK1-SIK3 over EPHA1-EPHA4 (IC50s = 0.145-2.1 µM), EPHB1-EPHB4 (IC50s = 0.607-22.6 µM), Abl1 (IC50 = 28.1 µM), JNK1 (IC50 = 23.2 µM), GAK (IC50 = 33.8 µM), and RSK1B (IC50 = >45 µM). MR22 (5 µM) induces cell cycle arrest at the G1 phase and reduces rapamycin-induced Akt phosphorylation in SKOV3 ovarian cancer cells.
| Cas No. | 3027761-24-3 | SDF | |
| 化学名 | 8-(4-aminobutyl)-6-(2,5-difluorophenyl)-2-(methylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one | ||
| Canonical SMILES | FC1=CC=C(C=C1C2=CC3=C(N=C(N=C3)NC)N(C2=O)CCCCN)F | ||
| 分子式 | C18H19F2N5O | 分子量 | 359.380806 |
| 溶解度 | DMSO: Sparingly soluble: 1-10 mg/ml | 储存条件 | -20°C |
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7826 mL | 13.9128 mL | 27.8256 mL |
| 5 mM | 556.5 μL | 2.7826 mL | 5.5651 mL |
| 10 mM | 278.3 μL | 1.3913 mL | 2.7826 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















